The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

A research team from the University of Cologne conducted one of the most comprehensive studies on dopamine and ...

Discover the impact of dopamine on the brain's reward circuit, from pleasure to addiction, and how to find balance.

In one of the largest studies of its kind, researchers found that increasing dopamine levels with L-DOPA made people slightly ...

Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.

"As Parkinson’s disease becomes more common and patients live longer, researchers are stepping up efforts to find better treatments, with nearly half of current studies focused on therapies that could ...

New research shows that dopamine decreases impulsivity by 20% compared to placebo, as shown by participants' willingness to ...